Compare First Citizens BancShares Inc (FCNCA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Recursion Pharmaceuticals Inc — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $24.84B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: First Citizens BancShares Inc is far larger — about 14× Recursion Pharmaceuticals Inc's market cap, and First Citizens BancShares Inc pays a 0.38% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FCNCA | RXRX | |
|---|---|---|
Market Cap | $24.84B | $1.78B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $6.79 |
52-Week Low | $1.64K | $2.84 |
Dividend Yield | 0.38% | — |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,218.49, down 0.85% on the day, with strong technical indicators showing a bullish trend. The company demonstrates solid fundamentals with a P/E of 11.98, net income margin of 25.23%, and consistent earnings beats in recent quarters. Recent business developments include expansion of working capital finance services and strategic leadership appointments to drive growth across central U.S. markets.
FCNCA presents a mixed outlook with strong profitability metrics and positive earnings momentum offset by cautious analyst sentiment (81.82% hold rating). The stock trades below consensus price target of $2,310, offering potential upside, though risks include contracting net interest margins and elevated uninsured deposits at 38.3% of total deposits.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
